Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(20%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
20%
Ph not_applicable
2
40%
Ph phase_2
2
40%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
2(40.0%)
N/ANon-phased studies
2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Completed(2)

Detailed Status

Completed2
Not yet recruiting2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (20.0%)
Phase 22 (40.0%)
N/A2 (40.0%)

Trials by Status

completed240%
not_yet_recruiting240%
recruiting120%

Recent Activity

1 active trials
Showing 5 of 5
not_yet_recruitingnot_applicable

Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke

NCT07483281
recruitingphase_2

Tenecteplase Plus Urinary Kallidinogenase for Acute Ischemic Stroke (TUKIS)

NCT07283159
completedphase_1

Study to Assess PK, Safety and Tolerability in Healthy Subjects

NCT06380699
not_yet_recruitingnot_applicable

Effects of Human Urinary Kallidinogenase on Early Improvement and Functional Outcomes in Acute Ischemic Stroke (TK-SPEED)

NCT06132880
completedphase_2

Multi-modality MRI Study on Effect to Collateral Circulation and Blood Perfusion of Acute Cerebral Infarction by Human Urinary Kallidinogenase

NCT02259738

Clinical Trials (5)

Showing 5 of 5 trials
NCT07483281Not Applicable

Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke

Not Yet Recruiting
NCT07283159Phase 2

Tenecteplase Plus Urinary Kallidinogenase for Acute Ischemic Stroke (TUKIS)

Recruiting
NCT06380699Phase 1

Study to Assess PK, Safety and Tolerability in Healthy Subjects

Completed
NCT06132880Not Applicable

Effects of Human Urinary Kallidinogenase on Early Improvement and Functional Outcomes in Acute Ischemic Stroke (TK-SPEED)

Not Yet Recruiting
NCT02259738Phase 2

Multi-modality MRI Study on Effect to Collateral Circulation and Blood Perfusion of Acute Cerebral Infarction by Human Urinary Kallidinogenase

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5